Navigation Links
MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
Date:5/4/2011

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- The Center for Best Practices, a new affiliate organization of Medicaid Health Plans of America (MHPA), today announced the receipt of financial sponsorship from Raritan, NJ-based pharmaceutical company Ortho-McNeil-Janssen Pharmaceuticals, Inc. to engage Medicaid managed care clinical leadership on the best ways to treat plan members with schizophrenia, bipolar disorder, and other severe mental illness (SMI).  The initiative called "Best Practices to Integrate Care for Seriously Mentally Ill Beneficiaries" will begin immediately and will take a multifaceted approach to raising the level of understanding at Medicaid health plans including creating web-based educational programs and publishing resources to aid in management of SMI.

"The mission of the Center for Best Practices is to inform and educate Medicaid health plans on how best to treat the low-income population they serve, with some of the Center's priorities falling very much in line with the goals of this effort," said Thomas L. Johnson, MHPA's President and CEO.  "The Center's focus on highlighting effective Medicaid health plan programs and improving care coordination and treatment adherence, especially in the area of medical and behavioral health services, dovetails well with the commitment of Ortho-McNeil-Janssen to improving the health of patients affected by these diseases. We are proud to have such a dedicated and innovative company that has done so much in the field of mental health as the Center's first-ever sponsor."

The Center will provide web content and resources such as data and information for effectively serving those Medicaid patients with SMI.  The Center also will partner with advocacy groups representing the SMI population to better understand the issues specific to this disease.  Educational webinars on topics ranging from increasing adherence to ensuring effective transitions from inpatient to outpatient care are also planned.  In addition, the Center will publish a compilation of health plan best practices that details specific examples of progress in treating those with SMI. This compendium will also include statistics and other mental health resources that may be useful to Medicaid health plans.

"People with life-altering diseases such as schizophrenia or bipolar disorder often experience a number of issues including higher rates of unemployment, poverty and even homelessness," Johnson noted. "Coordinated care to address the physical and mental health needs of this special population is needed.  Given the integrated systems of care inherent in Medicaid health plans, disseminating knowledge of what works best for those with serious mental illness is a very important step in ensuring the best possible care for these patients."

Ortho-McNeil-Janssen Pharmaceuticals, Inc. is the first pharmaceutical company sponsor for this project. The sponsorship will ultimately be expanded to include multiple pharmaceutical company sponsors, however sponsors will have no control or influence on initiatives conducted by the MPHA Center for Best Practices.

About Medicaid Health Plans of America

Medicaid Health Plans of America (MHPA) is the leading trade association solely focused on representing Medicaid health plans. MHPA provides advocacy, research and organized forums that support the development of policy solutions to enhance the delivery of quality health care. For more information, visit Medicaid Health Plans of America at http://www.mhpa.org or email at info@mhpa.org.

Media Contact:
Joe Reblando
202-857-5722
jreblando@mhpa.org


'/>"/>
SOURCE Medicaid Health Plans of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
6. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology:
(Date:4/26/2017)... Plano, TX (PRWEB) , ... April 26, 2017 ... ... to confer the distinction of Customer Excellence upon National Registry of Emergency ... , “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced ... farmers produce more and better food, with fewer resources. It highlights the business’ ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
Breaking Medicine News(10 mins):